Find Academic Supervisors

Joshua AkeyView profile

Professor

• Genomics
• Population Genetics
• Evolutionary Biology
• +4 more

Joshua Akey is a Professor at Princeton University's Lewis-Sigler Institute for Integrative Genomics, specializing in the biology and evolution of genomes. His interdisciplinary research spans yeast, dogs, and humans, integrating experimental, computational, and theoretical methods to address complex genetic questions. Research Focus: Human population genomics, yeast functional genomics, and canine adverse drug response genetics. Collaborations: Katrina Mealey (Washington State University), Evan Eichler (University of Washington). Key Themes: Archaic introgression, adaptive evolution, and the genetic architecture of phenotypic variation. The Akey Lab leverages large-scale datasets and statistical approaches to explore genome-wide selection patterns, copy number variation, and evolutionary mechanisms. Recent publications emphasize comparative genomics, longevity in companion dogs, and Neanderthal ancestry in African populations. Scientific Recognition: Recognized as a Best Scientific Figure of 2012 by Wired. Students: Ruby Redlich, Susie Song, Caroline (Cara) Weisman, Winnie Xu, Kaiqian Zhang.

Nicola ArmstrongView profile

Professor

• Applied Statistics
• Data Science
• Genetics
• +7 more

Nicola Armstrong is a Professor at Curtin University in Western Australia, where she serves in the School of Electrical Engineering, Computing and Mathematical Sciences within the Faculty of Science and Engineering. She is currently the Discipline Lead for Mathematics and Statistics (2024-25) and serves as president of the Western Australian branch of the Statistical Society of Australia. Dr. Armstrong received her PhD from the Department of Statistics at UC Berkeley. Her academic journey has taken her from postdoctoral work in the Netherlands to positions at the Netherlands Cancer Institute as a senior statistician and the Garvan Institute as a senior bioinformatics officer before joining Curtin University. Her research spans multiple disciplines at the intersection of statistics, genomics, and biomedical science. Dr. Armstrong has made significant contributions to: Development of statistical methodology for genomic analysis Application of statistics to cancer research Studies of healthy ageing and dementia Genome-wide association studies (GWAS) Epigenetics and biomarker research Analysis of her recent publications reveals a strong focus on the genetic and epigenetic factors influencing brain structure, cognitive function, and age-related diseases. Her work often involves large-scale collaborative efforts through international consortia, particularly in the areas of neuroimaging genetics and dementia research. Many of her recent studies employ multi-omics approaches to understand the complex interplay between genetic variation, environmental factors, and disease outcomes. Dr. Armstrong actively contributes to the academic community through her teaching of statistics and data science courses at both undergraduate and postgraduate levels, including STAT1006 Regression and Non-parametric Statistics, STAT3001 Statistical Modelling, STAT4002 Introduction to Applied Statistics, STAT5009 Decision Methods and Predictive Analytics, and ACTL4003 Predictive Analytics Principles.

Patrick SullivanView profile

Professor

• Psychiatric Genetics
• Schizophrenia
• Major Depressive Disorder
• +3 more

Patrick Sullivan, MD, is the Ray M. Hayworth & Family Distinguished Professor of Psychiatry and Professor of Genetics at the University of North Carolina (UNC) Chapel Hill, and a Professor at Karolinska Institutet in Sweden. He leads the Center for Psychiatric Genomics and co-founded the Psychiatric Genomics Consortium. His research focuses on the genetic basis of psychiatric disorders such as schizophrenia, major depressive disorder, post-partum depression, and eating disorders, employing molecular genetics, epidemiology, and large-scale consortia. Sullivan has trained numerous post-doctoral researchers and maintains a lab with significant NIH and international funding. Education: MD, University of California, San Francisco BS in Biology, University of Notre Dame Research Interests: The Sullivan Lab integrates genetic, epidemiological, and clinical approaches to understand complex psychiatric disorders. Key areas include identifying genetic variants influencing disease etiology, pharmacogenetics of antipsychotics, and leveraging multi-country consortia to study shared genetic mechanisms across disorders. The lab emphasizes translational research to bridge genetic findings with clinical applications. Publications & Awards: Sullivan has over 400 peer-reviewed publications (h-index 114) and received the Ming Tsuang Lifetime Achievement Award. Recent work highlights shared genetic variants across eight psychiatric disorders and the role of mitochondrial dysregulation in schizophrenia. Grants & Collaborations: Primary funders include the NIH and Swedish Research Council. Sullivan splits time between UNC and Karolinska Institutet, fostering international collaborations. His lab engages in global initiatives like the Nordic OCD & Related Disorders Consortium and the Eating Disorders Genetics Initiative. Labs & Teams: Based in UNC’s School of Medicine and Karolinska’s Psychiatric Genomics Institute. Collaborations span epidemiology, biostatistics, and computational biology. Key lab members include Dr. Jin Szatkiewicz (copy number variation in schizophrenia), Dr. Jim Crowley (obsessive-compulsive disorder genetics), and project manager Dr. NaEshia Ancalade.

• Human Genetics
• Neurogenetics
• Autism Spectrum Disorders
• +4 more

Dr. Hande Kaymakcalan is an Assistant Professor in the Department of Neurosurgery at Yale School of Medicine. She holds an MD from Marmara University School of Medicine (1999) and completed her residency at Cook County Hospital (2003) and Yale University (2009). Her research focuses on the intersection of human genetics and neurodevelopmental disorders, particularly PTEN Hamartoma Tumor Syndrome (PHTS) in pediatric patients, the creation of Turkish PHTS patient registry, genetics of overgrowth disorders with intellectual disability, congenital heart disease, and autism spectrum disorders. Her work bridges clinical neurology with genetic research, emphasizing population-specific studies in Turkish cohorts. Analysis of Dr. Kaymakcalan's publication record reveals a strong emphasis on genetic mechanisms underlying neurodevelopmental disorders, with particular focus on mTOR signaling pathways, cortical neuronal migration defects, and genotype-phenotype correlations in rare genetic syndromes. Her research demonstrates consistent collaboration with leading geneticists and neuroscientists, with publications appearing in high-impact journals including Nature and Nature Genetics. Dr. Kaymakcalan maintains active collaborations with researchers including Kaya Bilguvar, Katsuhito Yasuno, Murat Günel, Adife Gulhan Ercan-Sencicek, and Zeynep Erson Omay, with whom she has co-authored numerous publications. Her work has contributed significantly to understanding the genetic basis of neurodevelopmental conditions, particularly in Turkish populations. Her laboratory work centers on genetic analysis of neurodevelopmental disorders, with emphasis on creating population-specific registries and identifying novel genetic variants associated with complex phenotypes. Current research directions appear to be expanding into the molecular mechanisms of neuronal migration disorders and their relationship to mTOR signaling pathways.

Vardhman RakyanView profile

Professor

• Epigenetics
• Genomics
• Ribosomal DNA Variation
• +3 more

Vardhman Rakyan serves as Professor of Epigenetics and Deputy Director of Research at the Centre for Genomics and Child Health within the Blizard Institute, Faculty of Medicine and Dentistry at Queen Mary University of London. He joined the institution as a Lecturer in 2007 after completing postdoctoral training at the Sanger Institute. His academic background includes: BSc (Hons) Biochemistry from the University of Sydney PhD in Epigenetic Inheritance (1999-2002) at the University of Sydney under Prof. Emma Whitelaw CJ Martin Postdoctoral Fellowship at the Sanger Institute, Cambridge (2003-2007) with Dr. Stephan Beck Rakyan's research centers on how overlooked genomic elements—particularly ribosomal DNA (rDNA)—influence mammalian phenotypes through genetic and epigenetic variation. His lab investigates rDNA copy number variation (100-600 copies) and single nucleotide variants in human populations, integrating molecular genomics, computational biology, mouse models, and human cohorts to study gene-environment interactions and epialleles. Key focus areas include epigenetic inheritance mechanisms, the impact of early-life nutrition on rDNA epigenetics, and the role of rDNA variation in aging and complex diseases. His publication record demonstrates consistent contributions to epigenetics and genomics, with recent work revealing how rDNA genetic variation directly shapes epigenetic states across species and influences lifespan determination. The research bridges fundamental genomic mechanisms with translational applications in human health. Scientific recognition includes: CJ Martin Postdoctoral Fellowship Rakyan actively mentors students as an MBBS academic advisor and Experimental Pathology Research Project supervisor. His lab operates through collaborative grants supporting genomic studies of rDNA variation, epigenetic inheritance, and gene-environment interactions, though specific grant details remain undisclosed in source materials. The Rakyan Lab maintains a dynamic research environment with current members, former contributors, and international collaborators focused on uncovering molecular mechanisms of epigenetic regulation in health and disease.

Kelly VaughanView profile

Associate Professor

• Statistical Genetics
• Bioinformatics
• Genomics
• +3 more

Kelly Vaughan is the Chair and Associate Professor of Biology at King University. Her academic journey includes a BS in Biochemistry and Animal Science from Berry College, a PhD in Biochemistry from Texas A&M University, and postdoctoral work at the University of Alabama at Birmingham (UAB), where she later served as a Research Assistant Professor in Biostatistics. Her expertise spans statistical genetics, bioinformatics, and interdisciplinary genomics research. She transitioned to academia to focus on undergraduate research mentorship, emphasizing hands-on laboratory experience and Women in STEM advocacy. Her research integrates functional genomics and pathway analysis, addressing complex diseases such as obesity, rheumatoid arthritis, and cancer. A pivotal moment in her career was her 2015 cancer diagnosis, which underscored her commitment to holistic education and resilience. She actively involves students in regional and national conferences, fostering their integration into scientific communities. Her work highlights methodological rigor in genetic analysis and the ethical use of genomic data. Key contributions include studies on genetic loci associated with metabolic traits in Indigenous populations, gene expression in rheumatoid arthritis, and the impact of dietary interventions on aging biomarkers. Her teaching philosophy merges clinical relevance with cutting-edge research, aiming to inspire future scientists through both classroom and lab experiences.

Owen MichaelView profile

Professor

• Psychiatric Genetics
• Biological Psychiatry
• Neuroscience
• +3 more

Sir Michael Owen is a Professor of Psychological Medicine and Director of the Institute of Psychological Medicine and Clinical Neurosciences at Cardiff University's School of Medicine. His roles include Deputy Head of the School of Medicine, Director of the MRC Centre for Neuropsychiatric Genetics and Genomics, and past leadership positions such as Acting Dean and Deputy Pro Vice Chancellor for Research. He holds a PhD in Neuroscience and MB.ChB medical degree from Birmingham University. His research focuses on psychiatric genetics, biological psychiatry, and neuroscience, particularly schizophrenia and neuropsychiatric disorders. Notable contributions include identifying genetic risk factors through genome-wide association studies and investigating synaptic pathways linked to mental illness. His work bridges clinical research with translational science, emphasizing genomic insights into psychiatric conditions. Education: BSc (Birmingham, 1977), PhD (Neuroscience, 1982), MB.ChB (1983), MRCPsych (1987), FRCPsych (1997), FMedSci (1999), FLSW (2011). Awards: Queen’s Anniversary Prize, Lifetime Achievement Award (International Society of Psychiatric Genetics), Knight Bachelor (2014), and multiple lectureships/honorary professorships worldwide. He leads major research initiatives, including the MRC Centre for Neuropsychiatric Genetics and Genomics, and has authored over 1,000 publications with an h-index of 120. His interdisciplinary approach integrates genetics, psychiatry, and neuroscience to advance understanding of mental health disorders.

• Neuroimaging
• Functional Magnetic Resonance Imaging
• Language
• +7 more

Professor Katie McMahon is a leading academic at Queensland University of Technology (QUT), holding dual roles as Deputy Director of the Herston Imaging Research Facility and Academic Lead for Research at the School of Clinical Sciences. With a PhD from the University of Queensland, her expertise spans neuroimaging and cognitive neuroscience. Research Focus: Neurobiology of language, genetics of brain development, and neuroimaging applications in stroke, epilepsy, and pediatric language disorders (e.g., autism). Collaborations: Works with Queensland Health and philanthropic organizations on brain imaging and musculoskeletal studies. Teaching: Contributes to radiation therapy and MR-guided radiation therapy courses, emphasizing clinical sciences education. Recent Research Trends: Her work bridges neuroimaging techniques (fMRI, DTI) with cognitive deficits, exploring lexical processing, aphasia recovery, and genetic influences on brain structure. Recent studies address stroke rehabilitation, epilepsy language deficits, and fatty liver imaging protocols. Grants & Projects: Lead investigator on grants like “Predicting and Promoting Aphasia Recovery” (2016) and “Enhancing Language Learning in Ageing with Exercise” (2016). Labs/Teams: Active in the Herston Imaging Research Facility and National Imaging Facility committees.

• Genetics
• Genomics
• Proteomics
• +3 more

Shrikant Mane is a Professor of Genetics at Yale University, affiliated with the Yale School of Medicine. He holds dual directorships at the Yale Center for Genome Analysis (YCGA) Shared Resource and the Keck Biotechnology Resource Laboratory. His research focuses on genomic and proteomic technologies, including microarray and high-throughput DNA sequencing. Mane has over 25 years of academic and industry experience, with significant NIH funding and 125+ publications. He leads the Yale Center for Mendelian Genomics and pursues neuroscience research alongside his lab leadership roles. Education: PhD in Cancer Biology from the University of Bombay (1985), Postdoctoral training at Johns Hopkins University School of Medicine. His labs have provided genomic services to over 350 principal investigators globally. Collaborations include work with renowned researchers like Richard Lifton and Murat Günel. Research Interests: Genomic technologies, genetic basis of kidney diseases, neurodevelopmental disorders, and translational genomics. His work bridges clinical and basic science, with emphasis on applying genomic analyses to uncover disease mechanisms. Grants & Funding: Secured an $11.2M NHGRI grant for the Yale Center for Mendelian Genomics. Active in multi-institutional projects addressing congenital anomalies, kidney disorders, and neurovascular malformations. Labs & Teams: Directs YCGA and Keck Biotech labs, which provide cutting-edge genomic services including library preparation, sequencing, and bioinformatics. These facilities support over 72 national and 16 international institutions.

• Epilepsy
• Antiepileptic Drugs
• Drug Resistance
• +7 more

Dr. Graeme Sills is a Senior Lecturer in Pharmacology and Director of Education (Cardiovascular & Metabolic Health) at the University of Glasgow’s School of Life Sciences. His contact details include the email Graeme.Sills@glasgow.ac.uk and a telephone number (0141 330 4140). He graduated with a first-class honours degree in Pharmacology from the University of Glasgow in 1990 and earned his PhD in 1994, focusing on experimental seizure models and antiepileptic drugs. His research interests center on epilepsy drug mechanisms, clinical neuropharmacology, and drug resistance. Areas of exploration include blood-brain barrier transporters, genomics, inflammation, and oxidative stress in epilepsy. He has pioneered the use of non-mammalian species (e.g., Caenorhabditis elegans ) for antiseizure drug discovery, as seen in collaborative studies like the SANAD II trials. His work bridges preclinical and clinical research, emphasizing personalized medicine and therapeutic innovation. Dr. Sills has contributed to over 140 publications, including landmark studies on genetic predictors of drug resistance and biomarker identification. He collaborates with international consortia (e.g., Epi25, EuroEPINOMICS-CoGIE) and has authored book chapters on antiepileptic drug mechanisms and clinical trial methodologies. His research often integrates genetic, proteomic, and neurochemical approaches to understand epilepsy’s complex etiologies and improve treatment strategies. In education, he leads programs in cardiovascular and metabolic health, focusing on translating pharmacological research into teaching. His interdisciplinary work spans neuroscience, clinical pharmacology, and statistical analysis to address gaps in epilepsy drug development and patient outcomes.

• Genetics
• Neurodevelopmental Disorders
• Rare Diseases
• +7 more

Tjitske Kleefstra is a Full Professor in the Department of Clinical Genetics at Erasmus MC, a prominent academic medical center in the Netherlands. Her work is centered on rare genetic and neurodevelopmental disorders, with a particular focus on Kleefstra syndrome and related conditions involving epigenetic dysregulation. Her research interests span genetics, neurodevelopmental disorders, rare diseases, epigenetics, DNA methylation, and genomic diagnostics . She actively investigates genotype-phenotype correlations and leverages large-scale collaborative frameworks such as the Solve-RD consortium to improve diagnosis through genomic reanalysis. Her work underscores the value of patient and caregiver-reported data in rare disease research. The recent trend in her publications reflects a strong emphasis on genomic reanalysis, rare disease diagnostics, neurogenetics, and patient-centered outcomes . She contributes to high-impact research in journals such as Nature Medicine and European Journal of Human Genetics , often focusing on novel genetic variants, cohort characterization, and translational implications. No scientific awards were mentioned in the provided text. As a full professor and corresponding author on multiple studies, Dr. Kleefstra likely supervises researchers and contributes to grant-funded projects, particularly within international consortia like Solve-RD. While specific students are not listed, her leadership in multi-center studies indicates an active mentoring and collaborative role. She is part of a broad research network in clinical genetics and genomics, collaborating with teams across Europe. Her work is integrated into large data-sharing and reanalysis initiatives, reflecting a team-based, collaborative approach to advancing rare disease diagnostics and understanding.

Christelle Moufawad El AchkarView profile

Academic

• Epilepsy
• Pediatric Neurology
• Genetic Epilepsy
• +3 more

Dr. Christelle Moufawad El Achkar is an Instructor of Neurology at Harvard Medical School and Assistant in the Department of Neurology at Boston Children's Hospital. She specializes in epilepsy care with a particular focus on pediatric patients and genetic aspects of seizure disorders. Her work is centered at the Epilepsy Center, one of the nation's few Level 4 pediatric epilepsy centers recognized by the National Association of Epilepsy Centers. Dr. El Achkar completed her medical education at the American University of Beirut in 2008, followed by an internship at Rainbow Babies & Children's Hospital in Cleveland (2011), and neurology residency and fellowship at Boston Children's Hospital (2014-2016). She is board certified in both Child and Adolescent Neurology and Epilepsy by the American Board of Psychiatry and Neurology. Her research primarily focuses on the genetic underpinnings of epilepsy, with numerous publications examining genetic variants associated with pediatric-onset epilepsy, developmental and epileptic encephalopathies, and specific gene-related epilepsy syndromes. Her work spans from basic molecular mechanisms to clinical applications of genetic testing and precision medicine approaches for rare genetic epilepsies. She has contributed significantly to characterizing conditions related to genes including GABRB2, CACNA1E, PACS2, and others. Dr. El Achkar's publication record demonstrates a consistent trajectory of impactful research in epilepsy genetics, with recent work focusing on the diagnostic utility of exome sequencing and the development of patient-customized therapies for rare genetic disorders. Her research bridges clinical neurology with molecular genetics to advance understanding and treatment of genetic epilepsies. As part of Boston Children's Hospital's Epilepsy Center, she contributes to a comprehensive program that provides testing, evaluation, treatment, and counseling for children with epilepsy and seizures through the full range of medical, dietary, noninvasive, and surgical treatments.

Jonathan KeatsView profile

Assistant Professor

• Multiple Myeloma
• Cancer Genomics
• Bioinformatics
• +4 more

Jonathan Keats, Ph.D., serves as an Assistant Professor at the Translational Genomics Research Institute (TGen) and holds the position of Scientific Director at the Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope. Additionally, he directs TGen's Bioinformatics division and the Collaborative Sequencing Center, which provides advanced genomic sequencing services to researchers worldwide. His work bridges cutting-edge genomics with clinical applications in cancer. Dr. Keats' educational journey includes: Ph.D. from the University of Alberta (2005), where he investigated the clinical and biological consequences of the t(4;14)(p16;q32) translocation in multiple myeloma under Dr. Linda Pilarski. Postdoctoral training at the Mayo Clinic with Dr. Leif Bergsagel, focusing on identifying novel genetic events in multiple myeloma pathogenesis. His research is predominantly centered on multiple myeloma, with secondary interests in other hematological malignancies and immunodeficiency syndromes. Dr. Keats employs innovative genomic and bioinformatic methodologies to dissect the molecular underpinnings of these diseases, particularly targeting pathways like NF-kB that drive tumor development, progression, and therapeutic resistance. His work aims to translate genomic discoveries into immediate clinical impact, aligning with TGen's ethos of 'helping someone today.' Analysis of Dr. Keats' publication record reveals a trajectory from early investigations of specific cytogenetic abnormalities (e.g., t(4;14)) to comprehensive genomic analyses. His landmark studies include the identification of NF-kB pathway mutations and participation in the Multiple Myeloma Genomics Initiative. Recent work leverages advanced sequencing technologies to uncover structural variants and epigenetic modifications, demonstrating a consistent focus on integrating multi-omics data to refine disease subtyping and identify therapeutic vulnerabilities in myeloma. Dr. Keats leads the Collaborative Sequencing Center at TGen, which utilizes state-of-the-art short-read, long-read (Oxford PromethION), and intermediate-read sequencers to provide gapless human genome assemblies. His laboratory at the Briskin Center conducts research on multiple myeloma genomics and is the lead site for the CoMMpass study, which has identified distinct myeloma subtypes based on genomic profiles. This work directly informs precision medicine approaches for myeloma patients.

• Medical Genetics
• Hereditary Cancer Syndromes
• Neurogenetics
• +5 more

Selma DEMİR is an Assistant Professor in the Department of Medical Genetics at Trakya University Faculty of Medicine, where she has served since July 2017. Her academic foundation includes a Doctoral Degree (2011), Master's Degree (2005), and Bachelor's Degree (2003). Her research focuses on medical genetics with emphasis on hereditary cancer syndromes, neurogenetics, chromosomal abnormalities, and rare genetic disorders. Key areas include molecular diagnostics of neurofibromatosis type 1, hereditary hemorrhagic telangiectasia, DOORS syndrome, and Turkish population-specific genetic variants. She employs advanced techniques including array CGH, targeted resequencing, and MLPA for genetic analysis. Analysis of her 15 most recent publications reveals strong focus on Turkish patient populations, novel pathogenic variant discovery, and genotype-phenotype correlations across diverse conditions including cancer syndromes, neurodevelopmental disorders, and dermatological conditions. Her work frequently addresses population-specific genetic architecture in Thrace region. En iyi sözlü sunum ödülü (2017, Ege University) Sözlü sunum üçüncülük ödülü (2016, Erciyes University) Tübitak Ulusal Bilim Teşvik Ödülü (2006) Her funded projects include TÜBAP-2015-161 on mitochondrial DNA mutations in migraine patients, completed research on copy number variations in azoospermic males (2014-2017), and ongoing studies of genetic predisposition in differentiated thyroid cancer patients in Trakya region. While no formal students are listed, her collaborative work includes extensive research teams across Turkish institutions focusing on clinical genetics applications.

• Psychiatry
• Neuroimaging
• Genetics
• +5 more

Dr. David Glahn is the Associate Chief for Research in the Department of Psychiatry at Boston Children's Hospital and Harvard Medical School, where he directs the Tommy Fuss Center for Neuropsychiatric Disease Research, the Early Psychosis Investigation Center (EPICenter), and the Neuropsychiatric Genetics Program (NPG). He received his PhD in Clinical Psychology from the University of Pennsylvania and completed a post-doctoral fellowship at the University of California at Los Angeles. Prior to joining Boston Children's Hospital and Harvard Medical School, Dr. Glahn served as Co-Director for the Division of Neurocognition, Neurocomputation, and Neurogenetics at the Yale University School of Medicine. Dr. Glahn's research program centers on discovering genes and environmental mechanisms that predispose individuals to affective and psychotic disorders across the lifespan. His work develops and applies neuroanatomic, functional neuroimaging, and neurocognitive endophenotypes in large-scale family-based studies. His research involves four broad scientific aims: identifying genes influencing risk for psychotic and affective disorders; specifying genetic and environmental influences on brain structure/function and cognitive ability; isolating factors involved in human cognitive and brain development during adolescence; and developing novel endophenotypes for psychiatric disorders. His recent publications demonstrate a strong focus on neuroimaging genetics, particularly examining structural brain differences across psychiatric disorders, the role of copy number variants in brain morphology, and the development of reference curves for brain metrics across the lifespan. His work often involves large-scale consortium efforts like ENIGMA, highlighting his collaborative approach to psychiatric research. Dr. Glahn's research has significant implications for early identification of psychosis risk and potential interventions to mitigate the development of full-blown disease by recognizing antecedents in young children. Dr. Glahn has received recognition for his contributions to understanding the genetic architecture of brain structure and function, with particular emphasis on developmental aspects of psychiatric disorders. His work bridges basic neuroscience with clinical applications, aiming to translate findings into improved diagnostic and intervention strategies. As a leader in the field, Dr. Glahn mentors junior researchers and collaborates extensively across institutions. His laboratory serves as a hub for innovative research on the biological underpinnings of psychiatric disorders, with particular focus on early identification and prevention strategies. His work on the gut-brain axis and somatic symptoms in psychosis represents innovative directions in understanding the complex interplay between physical and mental health in psychiatric conditions.